Cell therapy is a technology, which relies on replacing diseased or dysfunctional cells with healthy functioning ones. Cells mainly used for such advanced therapies are stem cells, because of their ability to differentiate into the specific cells required for repairing damaged or defective tissues or cells. Moreover, cell therapy finds its application in the development of regenerative medicines, which is a multidisciplinary area aimed at maintenance, improvement, or restoration of cell, tissue, or organ function using methods mainly related to cell therapy. In addition, cells such as blood and bone marrow cells, mature, immature & solid tissue cells, adult stem cells, and embryonic stem cells are widely used in cell therapy procedures. Moreover, transplanted cells including induced pluripotent stem cells (iPSCs), embryonic stem cells (ESCs), neural stem cells (NSCs), and mesenchymal stem cells (MSCs) are divided broadly into two main groups including autologous cells and non-autologous cells.
The rise in adoption of human cells over animal cells for cell therapeutics research, technological advancements in field of cell therapy, and the increase in incidence of diseases such as cancer, cardiac abnormalities, and others are the key factors that drive the growth of the market. Furthermore, implementation of stringent government regulations regarding the use of cell therapy is anticipated to restrict the growth of the market. On the contrary, surge in number of regulations to promote stem cell therapy and increase in funds for research in developing countries are expected to offer lucrative opportunities to the market in near future.
Recent advances in cell therapy include combining stem cell and tissue engineering methods to overcome the constraints of stem cells in human disease treatment and provide a fresh route to the regeneration of damaged tissues. A team of scientists from UCLA, the University of Washington and the Fred Hutchinson Cancer Research Center are developing an engineered hematopoietic stem and progenitor cells (HSPC) platform for the management of simian/human immunodeficiency virus (SHIV) infections. The team has created genetically modified blood-forming stem cells that express the ability to produce cells that can detect and destroy HIV-infected cells. They tested this novel platform on non-human primates, with satisfactory results. This is the first study to establish clinical relevance of HSPC-derived CAR T-cell therapy in animal models for HIV/AIDS Thermo Fisher Scientific launched an advanced data integrity laboratory management system for full regulatory compliance in 2018. Moreover, in 2018, Haifa in, Israel, Lonza opened her Collaborative Innovation. Further, in 2017, GE aid noninheritable straight line (UK) strengthened its cell medical care portfolio with a set of technologies for the cryopreservation of cellular materials.
The global cell therapy market is categorized on the basis of therapy type, therapeutic type, cell type, and region. On the basis of therapy type, the market is segregated into autologous and allogenic. Based on therapeutic type, it is classified into malignancies, musculoskeletal disorders, autoimmune disorders, dermatology, and others. On the basis of cell type, the market is segregated in to stem cell therapy and non-stem cell type. On basis of region, the market is studied across North America, Europe, Asia-Pacific, and LAMEA.
The report provides a comprehensive analysis of the leading companies operating in the global cell therapy market are Kolon Tissue Gene, Inc., Osiris Therapeutics, Inc., JCR Pharmaceuticals Co. Ltd., NuVasive, Inc., Pharmicell Co Ltd., Vericel Corporation, Fibrocell Science Inc., Anterogen.co., Ltd., Stemedica Cell Technologies, Inc., Pharmicell Co., Ltd., and Medipost Co., Ltd.
Key Benefits for Stakeholders
- The report provides an extensive analysis of the cell therapy market size, current market trends and future estimations of the market.
- The cell therapy analysis is comprehensively covered with respect to the component, application, and region.
- The cell therapy estimations in this report are based on high-end analysis of the key developments for 2018–2026.
- Recent developments, key manufacturers, and top player positioning are listed in this report to analyze the competitive scenario of the cell therapy market.
Key Market Segments
By Cell Type
- Stem Cell
- Bone Marrow
- Umbilical Cord-Derived
- Adipose-Derived Stem Cell
- Non-stem Cell
By Therapy Type
- Musculoskeletal Disorders
- Autoimmune Disorders
By End User
- Hospital & Clinics
- Academic & Research Institutes
- North America
- Rest of Europe
- Rest of Asia-Pacific
- Saudi Arabia
- South Africa
- Rest of LAMEA